(Q79257100)
Statements
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863) (English)
Beex L
Rose C
Mouridsen H
Nooij M
Estape J
Paridaens R
Piccart M
Gorlia T
Lardenoije S
12 October 2006